Long-Acting PTH Compound for Hypoparathyroidism Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypoparathyroidism, such as high-dose active vitamin D and calcium, lead to adverse effects like nephrocalcinosis and renal insufficiency, and short-acting PTH molecules fail to adequately manage calcium homeostasis and urinary calcium excretion.
Innovation Solution
A long-acting PTH compound is administered daily to patients, allowing for the titration off of standard care within four weeks, maintaining normal serum calcium levels and reducing the need for calcium and active vitamin D supplements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose active vitamin D and calcium are administered to treat hypoparathyroidism, then serum calcium levels are maintained, but adverse effects such as nephrocalcinosis and renal insufficiency occur
Solution Approach 1:
The invention changes the therapeutic approach from high-dose calcium and vitamin D administration to physiological-dose PTH administration. This parameter change in treatment modality and dosage enables maintenance of serum calcium levels while avoiding the harmful effects of supraphysiological calcium and vitamin D doses, specifically preventing nephrocalcinosis and renal insufficiency
Solution Approach 2:
PTH administration restores the body's natural calcium homeostasis mechanisms, allowing the kidneys and bones to self-regulate calcium levels appropriately. This self-service approach eliminates the need for high-dose calcium and vitamin D supplementation, thereby preventing treatment-related adverse effects while maintaining reliable serum calcium control
2Reliability
If short-acting PTH molecules are administered to treat hypoparathyroidism, then some calcium homeostasis is achieved, but urinary calcium excretion is not adequately controlled and calcium homeostasis cannot be maintained throughout the day
Solution Approach 1:
The invention employs a dynamic dosing strategy with physiological-dose PTH administered once or twice daily, allowing the body's calcium homeostasis mechanisms to respond naturally to PTH stimulation. This dynamic approach with appropriate dosing frequency maintains adequate PTH activity throughout the day, controlling both serum calcium levels and urinary calcium excretion effectively
Solution Approach 2:
The invention utilizes periodic administration of physiological-dose PTH at appropriate intervals (once or twice daily) to maintain continuous calcium homeostasis control. This periodic stimulation of the calcium-regulating system ensures adequate PTH activity throughout the day, addressing both the duration limitation and the urinary calcium excretion control issue
3Reliability
If high-dose calcium supplements are taken to treat hypoparathyroidism, then serum calcium levels are maintained, but the calcium x phosphate product increases leading to ectopic calcifications
Solution Approach 1:
The invention fundamentally changes the treatment parameter from high-dose calcium supplementation to physiological-dose PTH administration. This parameter change maintains serum calcium levels through natural physiological mechanisms rather than exogenous calcium loading, thereby preventing the formation of ectopic calcifications that result from elevated calcium x phosphate product
Solution Approach 2:
PTH administration enables the body's own calcium-regulating systems to maintain appropriate serum calcium levels without requiring high-dose calcium supplements. This self-regulating approach keeps the calcium x phosphate product within safe ranges, preventing ectopic calcification while reliably maintaining serum calcium homeostasis
Data Source
AI summary
The present invention relates to a PTH compound for use in the treatment of hypoparathyroidism, wherein the treatment comprises single daily administrations of the PTH compound to a patient and titrating the patient off of standard of care within four weeks from the time the first dose of the PTH compound was administered.